BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update
April 14, 2022 07:00 ET
|
BeyondSpring, Inc.
- Company to host call today, April 14, 2022 at 8:00 am ET - Conference call can be accessed by dialing 877-451-6152 (U.S. and Canada) or +1-201-389-0879 (International). The passcode is...
BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022
April 08, 2022 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring Announces Organizational Streamlining
January 11, 2022 16:05 ET
|
BeyondSpring, Inc.
Resources to be Focused on Highest Value Business Activities 35% Reduction in Workforce in the U.S. Implemented to Preserve Long-Term Sustainability NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) --...
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
December 30, 2021 08:00 ET
|
BeyondSpring, Inc.
- Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant...
BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition
December 15, 2021 07:00 ET
|
BeyondSpring, Inc.
Adding plinabulin to a myelosuppressive chemotherapy regimen rapidly reversed (within 24 hours) chemotherapy-induced neutropenia and leukopenia in the PROTECTIVE-1 and -2 clinical studies, suggesting...
BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium
December 10, 2021 08:00 ET
|
BeyondSpring, Inc.
The two posters will be presented on Friday, December 10, 2021 8:00 AM to 9:30 AM EST NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”)...
BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)
December 01, 2021 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer...
BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 24, 2021 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today...
BeyondSpring Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
November 12, 2021 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today...
BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors
November 10, 2021 07:00 ET
|
BeyondSpring, Inc.
NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage biopharmaceutical company focused on the development of...